Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
出版年份 2020 全文链接
标题
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
作者
关键词
-
出版物
Cells
Volume 9, Issue 2, Pages 321
出版商
MDPI AG
发表日期
2020-01-29
DOI
10.3390/cells9020321
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer
- (2019) Mahmoud Hassani et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
- (2019) Esther Drent et al. CLINICAL CANCER RESEARCH
- Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
- (2019) Yushu Joy Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
- (2019) Alberto L. Horenstein et al. Frontiers in Immunology
- Killers 2.0: NK cell therapies at the forefront of cancer control
- (2019) Jonathan J. Hodgins et al. JOURNAL OF CLINICAL INVESTIGATION
- Exploiting Nanobodies’ Singular Traits
- (2018) Jessica R. Ingram et al. Annual Review of Immunology
- Nanobody Based Dual Specific CARs
- (2018) Stijn De Munter et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
- (2018) Na An et al. MOLECULAR PHARMACEUTICS
- Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
- (2018) Peter Bannas et al. Frontiers in Immunology
- CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
- (2018) Kerstin Schütze et al. Frontiers in Immunology
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
- (2017) Peter Bannas et al. Frontiers in Immunology
- Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo
- (2017) William Fumey et al. Scientific Reports
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
- (2016) Hans Klingemann et al. Frontiers in Immunology
- CD38 Monoclonal Antibody Therapies for Multiple Myeloma
- (2015) Sandy W. Wong et al. Clinical Lymphoma Myeloma & Leukemia
- Robust isolation of malignant plasma cells in multiple myeloma
- (2014) I. Frigyesi et al. BLOOD
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis
- (2009) K Weber et al. GENE THERAPY
- Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function
- (2009) Seyed Hamid Aghaee Bakhtiari et al. HYBRIDOMA
- Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma
- (2009) Keichiro Mihara et al. JOURNAL OF IMMUNOTHERAPY
- Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
- (2009) Janusz Wesolowski et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- A Multicolor Panel of Novel Lentiviral “Gene Ontology” (LeGO) Vectors for Functional Gene Analysis
- (2008) Kristoffer Weber et al. MOLECULAR THERAPY
- CD38 at the junction between prognostic marker and therapeutic target
- (2008) Silvia Deaglio et al. TRENDS IN MOLECULAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search